Nanomedicines improve drug bioavailability, the dose–response relationship, targeting
ability, efficacy and safety compared to conventional freely administered drugs …

Lipid‐based nanoparticles (LBNPs) are currently the most promising vehicles for nucleic
acid drug (NAD) delivery. Although their clinical applications have achieved success, the …

Lipid nanoparticles (LNPs) are the leading nonviral technologies for the delivery of
exogenous RNA to target cells in vivo. As systemic delivery platforms, these technologies …

Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases
worldwide. It is strongly associated with obesity, type 2 diabetes (T2DM), and other …

Necrosis is an overarching term that describes cell death modalities caused by (extreme)
adverse conditions in which cells lose structural integrity. A guaranteed consequence of …

The liver is the central metabolic organ of the body, regulating energy and lipid metabolism,
while also having potent immunological functions. Overwhelming the metabolic capacity of …

LSECs are a unique population of endothelial cells within the liver and are recognized as
key regulators of liver homeostasis. LSECs also play a key role in liver disease, as …

Non-alcoholic fatty liver disease (NAFLD) is considered as the hepatic manifestation of
metabolic syndrome, which is characterised by obesity, insulin resistance …

Autoimmunity and allergies affect a large number of people across the globe. Current
approaches to these diseases target cell types and pathways that drive disease, but these …

Despite the vital importance of monitoring the progression of nonalcoholic fatty liver disease
(NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), an efficient imaging …